Rinucumab

US Dry Age-Related Macular Degeneration Market and Competitive Landscape Report 2021: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Health, Optical, Ophthalmology, Clinical medicine, Branches of biology, Macular degeneration, Senescence, Stem cells, Macular dystrophy, Rinucumab

US Dry Age-Related Macular Degeneration Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Dry Age-Related Macular Degeneration pipeline products, Dry Age-Related Macular Degeneration epidemiology, Dry Age-Related Macular Degeneration market valuations and forecast, Dry Age-Related Macular Degeneration drugs sales and competitive landscape in the US.

Key Points: 
  • US Dry Age-Related Macular Degeneration Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Dry Age-Related Macular Degeneration pipeline products, Dry Age-Related Macular Degeneration epidemiology, Dry Age-Related Macular Degeneration market valuations and forecast, Dry Age-Related Macular Degeneration drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Dry Age-Related Macular Degeneration treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Dry Age-Related Macular Degeneration pipeline: Find out the products in clinical trials for the treatment of Dry Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Dry Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Dry Age-Related Macular Degeneration in the US
    Dry Age-Related Macular Degeneration drugs: Identify key products marketed and prescribed for Dry Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Dry Age-Related Macular Degeneration drugs sales: Find out the sales revenues of Dry Age-Related Macular Degeneration drugs in the US
    Dry Age-Related Macular Degeneration market valuations: Find out the market size for Dry Age-Related Macular Degeneration drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Dry Age-Related Macular Degeneration drugs market share: Find out the market shares for key Dry Age-Related Macular Degeneration drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Dry Age-Related Macular Degeneration products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005705/en/

Wet Age-Related Macular Degeneration Market to Flourish with a 4.5% CAGR and has a Promising Outlook with Emerging Therapies, Estimates DelveInsight

Retrieved on: 
Wednesday, March 17, 2021
Ophthalmology, Clinical medicine, Medicine, Angiology, Anti–vascular endothelial growth factor therapy, Macular degeneration, Monoclonal antibodies, Maculopathy, Rinucumab

The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
  • Anti-VEGF medications have been revolutionary for treating neovascular, or exudative, age-related macular degeneration, but unmet needs continue.
  • Also, it has been observed that Wet Age-Related Macular Degeneration is more prominent in females as compared to males.
  • The Wet Age-Related Macular Degeneration Market Report provides historical as well as forecasted epidemiological analysis segmented into:

Wet Age-Related Macular Degeneration Market to Flourish with a 4.5% CAGR and has a Promising Outlook with Emerging Therapies, Estimates DelveInsight

Retrieved on: 
Wednesday, March 17, 2021
Ophthalmology, Clinical medicine, Medicine, Angiology, Anti–vascular endothelial growth factor therapy, Macular degeneration, Monoclonal antibodies, Maculopathy, Rinucumab

The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
  • Anti-VEGF medications have been revolutionary for treating neovascular, or exudative, age-related macular degeneration, but unmet needs continue.
  • Also, it has been observed that Wet Age-Related Macular Degeneration is more prominent in females as compared to males.
  • The Wet Age-Related Macular Degeneration Market Report provides historical as well as forecasted epidemiological analysis segmented into:

Europe Age-Related Macular Degeneration Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 30, 2020
Pharmaceutical, Health, Optical, Ophthalmology, Clinical medicine, Organ systems, Macular degeneration, RTT, Senescence, Monoclonal antibodies, Macular dystrophy, Rinucumab

The "Europe Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Age-Related Macular Degeneration Market and Competitive Landscape - 2020, provides comprehensive insights into the Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following:
    Age-Related Macular Degeneration treatment options, Age-Related Macular Degeneration late stage clinical trials pipeline, Age-Related Macular Degeneration prevalence by countries, Age-Related Macular Degeneration market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Age-Related Macular Degeneration pipeline: Find out drugs in clinical trials for the treatment of Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Age-Related Macular Degeneration drugs: Identify key drugs marketed and prescribed for Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Age-Related Macular Degeneration drugs sales: Find out the sales value for Age-Related Macular Degeneration drugs by countries
    Age-Related Macular Degeneration market valuations: Find out the market size for Age-Related Macular Degeneration drugs in 2019 by countries.

Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 25, 2020
Health, Optical, Macular degeneration, RTT, Senescence, Organ systems, Biology, Life sciences, Macular dystrophy, Rinucumab

The "Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2020, provides comprehensive insights into the Dry Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Dry Age-Related Macular Degeneration market size and drug sales.
  • Dry Age-Related Macular Degeneration pipeline: Find out drugs in clinical trials for the treatment of Dry Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Dry Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Dry Age-Related Macular Degeneration by countries
    Dry Age-Related Macular Degeneration drugs: Identify key drugs marketed and prescribed for Dry Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Dry Age-Related Macular Degeneration drugs sales: Find out the sales value for Dry Age-Related Macular Degeneration drugs by countries
    Dry Age-Related Macular Degeneration market valuations: Find out the market size for Dry Age-Related Macular Degeneration drugs in 2019 by countries.

Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, & Market Shares - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 22, 2020
Health, Pharmaceutical, Macular degeneration, RTT, Senescence, Organ systems, Medical specialties, Clinical medicine, Monoclonal antibodies, Ophthalmology, Macular dystrophy, Rinucumab

The "Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020, provides comprehensive insights into the Wet Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Wet Age-Related Macular Degeneration market size and drug sales.
  • Wet Age-Related Macular Degeneration pipeline: Find out drugs in clinical trials for the treatment of Wet Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Wet Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Wet Age-Related Macular Degeneration by countries
    Wet Age-Related Macular Degeneration drugs: Identify key drugs marketed and prescribed for Wet Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Wet Age-Related Macular Degeneration drugs sales: Find out the sales value for Wet Age-Related Macular Degeneration drugs by countries
    Wet Age-Related Macular Degeneration market valuations: Find out the market size for Wet Age-Related Macular Degeneration drugs in 2019 by countries.

North America & Europe Age-related Macular Degeneration Therapeutics Market to Surpass US$ 15,122.8 Million by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Tuesday, September 15, 2020
Managed care, General Health, Health, Other Health, Life sciences, Industries, Biotechnology, Hoffmann-La Roche, Macular degeneration, Novartis, Rinucumab, Stem cells, Macular dystrophy

Key Trends and Analysis of the North America & Europe Age-related Macular Degeneration Therapeutics Market:

Key Points: 
  • Key Trends and Analysis of the North America & Europe Age-related Macular Degeneration Therapeutics Market:
    Key trends in the market are the increasing prevalence of age-related macular degeneration , the increasing number of approvals and launches of therapeutics for treatment of age-related macular degeneration, and strategic acquisitions, partnerships, and agreements by key players.
  • According to the American Academy of Ophthalmology 2020, the prevalence of age-related macular degeneration in the U.S. is roughly 8590% dry age-related macular degeneration and 1015% wet age-related macular degeneration.
  • The North America & Europe age-related macular degeneration therapeutics market is expected to exhibit a CAGR of 10.2% during the forecast period owing to launches of age-related macular degeneration therapeutics by market players.
  • Key players operating in the North America & Europe age-related macular degeneration therapeutics market are Novartis AG, Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Pfizer, Inc., and Valeant Pharmaceuticals International, Inc.
    North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type:
    North America & Europe Age-related Macular Degeneration Therapeutics Market, By Drug Type:

Worldwide Dry Age-Related Macular Degeneration Market Study to 2024 - Develop In-depth Knowledge of Competition and Markets - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 10, 2020
Health, Oncology, Ophthalmology, Medicine, Clinical medicine, Macular degeneration, RTT, Senescence, Monoclonal antibodies, Anti–vascular endothelial growth factor therapy, Rinucumab

The research report Global Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2020, provides comprehensive insights into the Dry Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • The research report Global Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2020, provides comprehensive insights into the Dry Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Dry Age-Related Macular Degeneration market size and drug sales.
  • This research covers the following:
    Dry Age-Related Macular Degeneration treatment options, Dry Age-Related Macular Degeneration late stage clinical trials pipeline, Dry Age-Related Macular Degeneration prevalence by countries, Dry Age-Related Macular Degeneration market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Dry Age-Related Macular Degeneration pipeline: Find out drugs in clinical trials for the treatment of Dry Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Dry Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Dry Age-Related Macular Degeneration by countries
    Dry Age-Related Macular Degeneration drugs: Identify key drugs marketed and prescribed for Dry Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Dry Age-Related Macular Degeneration drugs sales: Find out the sales value for Dry Age-Related Macular Degeneration drugs by countries
    Dry Age-Related Macular Degeneration market valuations: Find out the market size for Dry Age-Related Macular Degeneration drugs in 2019 by countries.

Global Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020 Study - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 10, 2020
Health, Oncology, Ophthalmology, Medicine, Monoclonal antibodies, Organ systems, Macular degeneration, RTT, Senescence, Breakthrough therapy, Anti–vascular endothelial growth factor therapy, Rinucumab

The "Global Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The research report Global Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020, provides comprehensive insights into the Wet Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following:
    Wet Age-Related Macular Degeneration treatment options, Wet Age-Related Macular Degeneration late stage clinical trials pipeline, Wet Age-Related Macular Degeneration prevalence by countries, Wet Age-Related Macular Degeneration market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Wet Age-Related Macular Degeneration pipeline: Find out drugs in clinical trials for the treatment of Wet Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Wet Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Wet Age-Related Macular Degeneration by countries
    Wet Age-Related Macular Degeneration drugs: Identify key drugs marketed and prescribed for Wet Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Wet Age-Related Macular Degeneration drugs sales: Find out the sales value for Wet Age-Related Macular Degeneration drugs by countries
    Wet Age-Related Macular Degeneration market valuations: Find out the market size for Wet Age-Related Macular Degeneration drugs in 2019 by countries.

Age-Related Macular Degeneration Markets, Pipeline, Drugs and Companies: 2016-2024

Retrieved on: 
Wednesday, May 13, 2020
Macular degeneration, RTT, Senescence, Organ systems, Medical specialties, Medicine, Monoclonal antibodies, Astellas Institute for Regenerative Medicine, Rinucumab

DUBLIN, May 13, 2020 /PRNewswire/ -- The "Global Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 13, 2020 /PRNewswire/ -- The "Global Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This research report provides comprehensive insights into the Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • The research analyzes and forecasts the Age-Related Macular Degeneration market size and drug sales.
  • Age-Related Macular Degeneration pipeline: Find out drugs in clinical trials for the treatment of Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Age-Related Macular Degeneration drugs: Identify key drugs marketed and prescribed for Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Age-Related Macular Degeneration drugs sales: Find out the sales value for Age-Related Macular Degeneration drugs by countries
    Age-Related Macular Degeneration market valuations: Find out the market size for Age-Related Macular Degeneration drugs in 2019 by countries.